David Friedman was appointed Director of Benitec Biopharma Inc. As of November 6, 2026, Benitec Biopharma Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 29, 2026, naming 1 appointment (Form 8-K, May 29, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Benitec Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Benitec Biopharma Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Benitec Biopharma Inc. files it.
Also on the record for Benitec Biopharma Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 29, 2026 | Stake report, Schedule 13G/A, by Franklin Resources, Inc. | 10.6% of the class | 5%+ stakes | Source |
| December 8, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 9.99% of the class | 5%+ stakes | Source |
| December 3, 2025 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 5.5% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13D/A, by SUVRETTA CAPITAL MANAGEMENT, LLC | 44.1% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13G/A, by Franklin Resources, Inc. | 14.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 11.3% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 11.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Benitec Biopharma Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Benitec Biopharma Inc. and the records around it.
Benitec Biopharma Inc. elsewhere on the record
- 5%+ stake filings Jan 2026
- Who owns it
Companies that share a holder
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Franklin Resources, Inc. also filed stake reports on 41 other companies: Adicet Bio, Inc. (Oct 2026), ALBEMARLE CORPORATION (Oct 2026), Andersen Group Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Benitec Biopharma Inc.
Get an email when Benitec Biopharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Benitec Biopharma Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Benitec Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Benitec Biopharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-29 | In | Director | 8-K, 2026-05-29 |
Who leads Benitec Biopharma Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: David Friedman, appointed (filed 2026-05-29).
New leaders reset buying decisions — get the Full Report on Benitec Biopharma Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Benitec Biopharma Inc., with the record behind each one.
Find candidates like Director at Benitec Biopharma Inc.Every change, in the filing's words
Appointed: David Friedman, Director
On May 22, 2026, the Board of Directors (the "Board") of Benitec Biopharma Inc. (the "Company") appointed David Friedman to serve as a director of the Board, effective as of such date.
- Mr. Friedman was appointed as a Class III member of the Board with a term lasting until the Company's 2028 annual meeting of stockholders.
- In connection with Mr. Friedman's appointment to the Board, the Board approved the grant of options to purchase 35,000 shares of the Company's common stock ("Common Stock") to Mr. Friedman (the "Options") under the Company's 2020 Equity and Incentive Compensation Plan (the "Equity Plan").
- The Options were granted as of May 26, 2026 (the "Grant Date") with an exercise price equal to the closing price of the Common Stock as quoted on the Nasdaq Stock Market LLC on the Grant Date.
- The Options will vest in full on the earlier of immediately prior to the next annual meeting of stockholders and the first anniversary of the Grant Date.
- The Options will be subject to the terms and conditions of the Equity Plan and the Company's standard form of stock option award agreement.
- Mr. Friedman will also be entitled to the compensation provided to the Company's non-employee directors as described in the Company's Definitive Proxy Statement on Schedule 14A filed on October 14, 2025.
- Ms. Boston will continue in her capacity as chief financial officer and secretary.
- The resignation from the Board was effective as of May 22, 2026.
Tools for this story
Each opens in a new tab, filled in for Benitec Biopharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.